Newsroom
Category
January 19, 2022
Dr. Virginia Kaklamani, Medicine/Hematology-Oncology and Mays Cancer Center, is the moderator of the discussion presented below. This is the final installment of a four-part series. The experts comment on two phase III trials that could change the treatment landscape for patients with metastatic HER2-positive breast cancer. Read More
January 6, 2022
Dr. Virginia Kaklamani, Medicine/Hematology-Oncology and Mays Cancer Center, is quoted in this article. Read story
January 5, 2022
Dr. Virginia Kaklamani, Medicine/Hematology-Oncology and Mays Cancer Center, is the moderator of the discussion presented in this article. The experts comment on two clinical trials of selective estrogen receptor degraders (SERDs) for treatment of metastatic breast cancer. Results of both trials were presented at the San Antonio Breast Cancer Symposium. Read story
January 3, 2022
Dr. Virginia Kaklamani, Medicine/Hematology-Oncology and Mays Cancer Center, is quoted in this article. Read story
December 22, 2021
Dr. Amelie Ramirez, Population Health Sciences, Mays Cancer Center and Institute for Health Promotion Research, is quoted in this article that mentions the National Cancer Institute study she is leading. The study aims to recruit 3,000 Hispanic and Latino Americans to understand cancer-related risk and outcomes among this population. Read story
December 21, 2021
Dr. Ruben Mesa, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson, gave a video interview about progress made in the treatment of myelofibrosis in 2021. Watch here